Next Article in Journal
Temporomandibular Disorders Slow Down the Regeneration Process of Masticatory Muscles: Transcriptomic Analysis
Previous Article in Journal
Correlation between the Neuropathic PainDETECT Screening Questionnaire and Pain Intensity in Chronic Pain Patients
Previous Article in Special Issue
Pulmonary Hypertension in Pregnancy: A Review
Review

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

1
Corpus Christi Medical Center, Department of Pulmonary Medicine, Corpus Christi, TX 78412, USA
2
Department of Pulmonary Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Camelia Diaconu
Received: 10 February 2021 / Revised: 1 April 2021 / Accepted: 2 April 2021 / Published: 7 April 2021
(This article belongs to the Special Issue Pulmonary Embolism Research)
Chronic thromboembolic pulmonary hypertension (CTEPH) is a specific type of pulmonary hypertension (PH) and the major component of Group 4 pulmonary hypertension (PH). It is caused by pulmonary vasculature obstruction that leads to a progressive increase in pulmonary vascular resistance and, ultimately, to failure of the right ventricle. Pulmonary thromboendarterectomy (PEA) is the only definitive therapy, so a timely diagnosis and early referral to a specialized PEA center to determine candidacy is prudent for a favorable outcome. Percutaneous balloon pulmonary angioplasty (BPA) has a potential role in patients unsuitable for PEA. Medical therapy with riociguat is the only PH-specific medical therapy currently approved for the treatment of inoperable or persistent CTEPH. This review article aims to revisit CTEPH succinctly with a review of prevailing literature. View Full-Text
Keywords: chronic thromboembolic pulmonary hypertension; pulmonary embolism; pulmonary thromboendarterectomy; percutaneous balloon pulmonary angioplasty; riociguat; ventilation-perfusion lung scan; computed tomography pulmonary angiography; pulmonary angiography chronic thromboembolic pulmonary hypertension; pulmonary embolism; pulmonary thromboendarterectomy; percutaneous balloon pulmonary angioplasty; riociguat; ventilation-perfusion lung scan; computed tomography pulmonary angiography; pulmonary angiography
Show Figures

Figure 1

MDPI and ACS Style

Sharma, M.; Levine, D.J. Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Medicina 2021, 57, 355. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57040355

AMA Style

Sharma M, Levine DJ. Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Medicina. 2021; 57(4):355. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57040355

Chicago/Turabian Style

Sharma, Munish, and Deborah J. Levine. 2021. "Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)" Medicina 57, no. 4: 355. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57040355

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop